Outcomes of lean, overweight or obese subjects with non-alcoholic fatty liver disease: a cohort study in China, Lan YQ, Lu Y, Li JF, Hu SQ, Chen SH, Wang YH, Yuan XJ, Liu HM, Wang XM, Wu SL, Wang L, 2022
Trend and Geographic Variation in Incidence and Prevalence of Inflammatory Bowel Disease in Regions Across China: A Nationwide Employee Study Between 2013 and 2016, Yang H, ZhouRN, Bai XY, Guo MY, Ruan GC, Wang L, Qian JM, 2022
Short-term weight loss decreased the risk of chronic kidney disease in men with incident non-alcoholic fatty liver disease, Hu SQ, Li XL, Sun YY, Wu SL, Lan YQ, Chen SH, Wang YH, Liao W, Wang XM, Zhang D, Yuan XJ, Gao JL, Wang L, 2022
Associations Between Metabolic Dysfunction-Associated Fatty Liver Disease and Extrahepatic Cancers: A Cohort in China, Yuan XJ, Wang XM, Wu SL, Chen SH, Wang YH, Wang JR, Lu Y, Sun YY, Fu QJ, Wang L, 2022
Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study, Peng HX, Wang SY, Wang MY, Ye Y, Xue E, Chen X, Wang XH, Fan M, Gao WJ, Qin XY, Wu YQ, Chen DF, Li J, Hu YH, Wang L, Wu T, 2022
Adherence to the dietary approaches to stop hypertension diet and non-alcoholic fatty liver disease, Sun YY, Chen SH, Zhao XY, Wang YH, Lan YQ, Jiang XZ, Gao X, Wu SL, Wang L, 2022
Blood manganese and nonalcoholic fatty liver disease: a cohort-based case-control study, Zhang D., Wu S., Lan Y., Chen S., Wang Y., Sun Y., Liao W., Wang L, 2022
Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study, Wang X., Wu S., Yuan X., Chen S., Fu Q., Sun Y., Lan Y., Hu S., Wang Y., Lu Y., Qu S., and Wang L, 2021
Associations between Nonalcoholic fatty liver disease and cancers in a large cohort in China, Wang ZY, Zhao XY, Chen SH, Wang YH, Cao LY, Liao W, Sun YY, Wang XM, Zheng Y, Wu SL, Wang L, 2021
Association between blood copper and nonalcoholic fatty liver disease according to sex, Lan Y, Wu S, Wang Y, Chen S, Liao W, Zhang X., Pan L., Jiang X., Zhang Y., Wang L, 2021
Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China, Li R, Lin X, Wang J, Wang X, Lu J, Liu Y., Cao Z., Ren S., Ma L., Jin Y., Zheng S., Hu Z, Wang L., Chen X, 2021
Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir, Wang X., Chen Y., Xu M., Cheng K., Liao W., Wang Y., Lu Y., Duan Z., Wang L, 2021
Reply-letter to the editor: copper deficiency and nonalcoholic fatty liver disease: the chicken or the egg?, Lan Y., Wang L, 2021
Entecavir combined with interferon-alpha is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B, Cheng K., Chen Y., Wang X., Xu M., Liao W., Duan X., Zhao X., Sun Y., Duan Z., Wang L, 2021
Time trends and other sources of variation in Helicobacter pylori infection in mainland China: a systematic review and meta-analysis, Li MM, Sun YY, Yang J, Martel Cd, Charvat H, Clifford GM, Vaccarella S, Wang L, 2020
Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China, Lei SY, Chen SH, Zhao XY, Zhang YM, Cheng KL, Zhang XH, Wang ZY, Sun YY, Wu SL, Wang L, 2020
Hospitalizations for Peptic Ulcer Disease in China: current features and outcomes, Zheng Y, Xue M, Cai Y, Liao SS, Yang H, Wang ZY, Wang XM, Zhang XG, Qian JM, Wang L, 2020
Screen-detected gallstone disease and risk of liver and pancreatic cancer: The Kailuan Cohort Study, Zhao XY, Wang N, Sun YY, Zhu GL, Wang YH, Wang ZY, Zhang YM, Cheng KL, Wang GD, Wu SL, Wang L, 2020
Out-of-pocket payments and economic consequences from tuberculosis care in eastern China: income inequality, Liu Y, Cu XH, Wang XM, Wang ZY, Wang YH, Zhang H, Wang L, 2020
